

# INFECTION CONTROL

---



## EDITORIAL

### **The Relationship Between APIC and SHEA: "Closely Watched Trains"**

George W. Counts, MD

## ORIGINAL ARTICLES

### **Survey on Testing Criteria and Reporting Methods for Human Immunodeficiency Virus Serologic Tests in Veterans Administration Medical Centers**

Susan Mottice, PhD; Sego Matsumiya, RN; Larry Reimer, MD

### **Inactivation of Human Immunodeficiency Virus by Betadine**

Joan C. Kaplan, PhD; David C. Crawford, BS; Amy G. Durno, BS;  
Robert T. Schooley, MD

### **Diffusion and Adoption of CDC Guidelines for the Prevention and Control of Nosocomial Infections in US Hospitals**

David D. Celentano, ScD; Laura L. Morlock, PhD; Faye E. Malitz, BS

### **The Detection of Blood on Nonporous Environmental Surfaces: An Approach for Assessing Factors Contributing to the Risk of Occupational Exposure to Blood in the Autopsy Suite**

Lorraine R. Beaumont, DrPH

### **Brief Report: An Outbreak of Scabies Among Employees in a Hospital-associated Commercial Laundry**

Michelle C. Thomas; Dale H. Giedinghagen; Gerald L. Hoff, PhD

## SPECIAL SECTIONS

### **Topics in Clinical Microbiology: *Vibrio vulnificus***

Hilda Ratner, BA, MA



# **Maximized**

**The HR<sup>™</sup> Needle—a Simple**





# **Protection**

**Solution to High-Risk Situations**





# The Latest On USE AND RE-USE

**EPA ACCEPTED:** For complete disinfection (including T.B. activity)

**“SPORICIDIN, DILUTED 1:16, IS TUBERCULOCIDAL AND CAN BE USED AND RE-USED FOR 30 DAYS FOR 100% HOSPITAL LEVEL DISINFECTION IN 10 MINUTES AT TRUE ROOM TEMPERATURE, 68°F AND ABOVE• (REG. #8383-5).”**

### Important Product Information:

Sporicidin is the **ONLY** dilutable glutaraldehyde-based 10 minute disinfectant that is registered for tuberculocidal re-use without heating. Respiratory and other equipment were used in the studies supporting the re-use claims. It is recommended for respiratory therapy and operating room instruments and equipment.

**Sporicidin is recommended by all major scope manufacturers.**

**\*\* Cidex now must be heated to 77°F / 25°C for 45 minutes for tuberculocidal activity.** Cidex, and Cidex type products, require a much higher glutaraldehyde concentration (2%) for disinfection and are less effective than Sporicidin, a glutaraldehyde (0.13%)-phenate complex.

Under the most stringent and scientific guidelines, Sporicidin is the best sterilizing/disinfecting product available.

*Curtis L. Lynch, M.D.*  
Curtis L. Lynch, M.D., M.P.H.  
Medical Director  
(800) 424-3733



**Sporicidin<sup>®</sup>**  
**INTERNATIONAL**  
4000 MASSACHUSETTS AVENUE, N.W.  
WASHINGTON, D.C. 20016



# INFECTION CONTROL®

## Table of Contents

### EDITORIAL

- The Relationship Between APIC and SHEA:  
"Closely Watched Trains"** 404  
George W. Counts, MD

### ORIGINAL ARTICLES

- Survey on Testing Criteria and Reporting Methods for Human  
Immunodeficiency Virus Serologic Tests in Veterans  
Administration Medical Centers** 407  
Susan Mottice, PhD; Segō Matsumiya, RN; Larry Reimer, MD
- Inactivation of Human Immunodeficiency Virus by Betadine** 412  
Joan C. Kaplan, PhD; David C. Crawford, BS; Amy G. Durno, BS;  
Robert T. Schooley, MD
- Diffusion and Adoption of CDC Guidelines for the Prevention  
and Control of Nosocomial Infections in US Hospitals** 415  
David D. Celentano, ScD; Laura L. Morlock, PhD;  
Faye E. Malitz, BS
- The Detection of Blood on Nonporous Environmental Surfaces:  
An Approach for Assessing Factors Contributing to the Risk of  
Occupational Exposure to Blood in the Autopsy Suite** 424  
Lorraine R. Beaumont, DrPH
- Brief Report: An Outbreak of Scabies Among Employees in a  
Hospital-associated Commercial Laundry** 427  
Michelle C. Thomas; Dale H. Giedinghagen; Gerald L. Hoff, PhD

### SPECIAL SECTIONS

- Topics in Clinical Microbiology: *Vibrio vulnificus*** 430  
Hilda Ratner, BA, MA

### DEPARTMENTS

- |                                |     |                           |     |
|--------------------------------|-----|---------------------------|-----|
| <b>Information for Authors</b> | 399 | <b>Book Reviews</b>       | 434 |
| <b>Letters to the Editor</b>   | 400 | <b>Calendar of Events</b> | 436 |

---

**The ideas and opinions expressed by contributing authors do not  
necessarily reflect those of the editors or publisher.**

---

**Publisher:** Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: (609) 848-1000.

**Copyright 1987:** All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**Subscriptions.** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, Mansui Bldg., 9-18, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101, Japan. Subscription rates in the US and possessions: Individual: One year—\$40.00; Two years—\$66.00; Three years—\$94.00. Institutional: One year—\$55.00; Two years—\$92.00; Three years—\$128.00; Canada: \$15.00 additional each year; all other countries: \$25.00 additional each year. Single copies of current issues may be obtained for \$7.00, United States and possessions; \$13.00 all other countries.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. **Postmaster:** Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.



## EDITOR

Richard P. Wenzel, MD, MSc  
Iowa City, Iowa

## SENIOR

### ASSOCIATE EDITOR

William Schaffner, MD  
Nashville, Tennessee

### ASSOCIATE EDITORS

Sue Crow, MSN, RN  
Shreveport, Louisiana

John E. McGowan, Jr., MD  
Atlanta, Georgia

Dennis G. Maki, MD  
Madison, Wisconsin



SLACK Incorporated  
6900 Grove Road  
Thorofare, New Jersey 08086

## Publisher

Richard N. Roash

## Editorial Director

Donna Carpenter

## Senior Editor/Development

John C. Carter

## Editorial Coordinator

Sandra L. Patterson

## Assistant Editor

Dawn A. Zwick

## Editorial Assistant

Mary Lou Jerrell

## Production Manager

Jim Griffin

## Production Coordinator

Lester Robeson

## Circulation Manager

Kevin J. Fenton

## Advertising Manager

Randall Roash

## Advertising

### Sales Representative

Wayne M. McCourt

### Advertising Sales

#### Coordinator

Betty Martz

## Classified

### Advertising Representative

Donna M. Coles

## EDITORIAL OFFICES

C41 General Hospital  
University of Iowa Hospitals and Clinics  
Iowa City, Iowa 52242  
(319) 356-0464

William J. Hausler, Jr., PhD

R. Michael Massanari, MD, MS

Michael Pfaller, MD

Robert F. Woolson, PhD

### Managing Editor

Marikay Klein

## EDITORIAL

### ADVISORY BOARD

Robert C. Aber, MD  
Hershey, Pennsylvania

Paul Arnow, MD  
Chicago, Illinois

Charles S. Bryan, MD  
Columbia, South Carolina

John P. Burke, MD  
Salt Lake City, Utah

Mary Castle, MPH, RN  
Berkeley, California

Marie B. Coyle, PhD  
Seattle, Washington

William Craig, MD  
Madison, Wisconsin

Burke A. Cunha, MD  
Mineola, New York

Richard E. Dixon, MD  
Trenton, New Jersey

Leigh G. Donowitz, MD  
Charlottesville, Virginia

Mark Eggleston, PharmD  
Washington, DC

Harvey A. Elder, MD  
Loma Linda, California

Bruce Farber, MD  
Pittsburgh, Pennsylvania

Martin S. Favero, PhD  
Atlanta, Georgia

Peter C. Fuchs, MD, PhD  
Portland, Oregon

Richard A. Garibaldi, MD  
Farmington, Connecticut

Angella Goetz, MEd, RN  
Pittsburgh, Pennsylvania

Donald A. Goldmann, MD  
Boston, Massachusetts

Dieter H.M. Gröschel, MD  
Charlottesville, Virginia

Peter A. Gross, MD  
Hackensack, New Jersey

Karen Hadley, MPH, RN  
New Orleans, Louisiana

David K. Henderson, MD  
Bethesda, Maryland

Peter N.R. Heseltine, MD  
Los Angeles, California

Cyrus C. Hopkins, MD  
Boston, Massachusetts

Allen B. Kaiser, MD  
Nashville, Tennessee

Donald L. Kaiser, DrPH  
Charlottesville, Virginia

Elaine Larson, PhD  
Cabin John, Maryland

Harold Laufman, MD, PhD  
New York, New York

Barbara McArthur, PhD, RN  
Detroit, Michigan

Rob Roy MacGregor, MD  
Philadelphia, Pennsylvania

C. Glen Mayhall, MD  
Richmond, Virginia

Patti J. Miller, MS  
Charlottesville, Virginia

Harry C. Nottebart, Jr., JD, MD  
Richmond, Virginia

Michael T. Osterholm,  
PhD, MPH  
Minneapolis, Minnesota

James E. Peacock, Jr., MD  
Winston-Salem, North Carolina

Frank S. Rhame, MD  
Minneapolis, Minnesota

William A. Rutala, PhD, MPH  
Chapel Hill, North Carolina

William E. Scheckler, MD  
Madison, Wisconsin

Walter E. Stamm, MD  
Seattle, Washington

Charles W. Stratton, MD  
Nashville, Tennessee

Richard L. Sweet, MD  
San Francisco, California

George H. Talbot, MD  
Philadelphia, Pennsylvania

Timothy R. Townsend, MD  
Baltimore, Maryland

James Veazey, MD  
Albany, New York

## FOREIGN

### ADVISORY BOARD

Graham Ayliffe, MD, FRCPath.  
Birmingham, England

Professor G. Berencsi  
Szeged, Hungary

David Birnbaum, MPH  
Sidney, British Columbia, Canada

Professor Jaap Dankert  
Groningen, Netherlands

Professor Dr. F. Daschner  
Freiburg, West Germany

Lars O. Kallings, MD  
Stockholm, Sweden

Professor W.B. Kędzia  
Sieroca, Poland

Professor A.P. Krasilnikow  
Minsk, USSR

Professor Dr. W. Marget  
Munich, West Germany

Jonathan L. Meakins, MD,  
FRCSC, FACS  
Montreal, Canada

Bertil Nyström, MD  
Huddinge, Sweden

Ian Phillips, MA, MD, MRCPath.  
London, England

Samuel Ponce de Leon, MD  
Mexico City, Mexico

Hans Reber, MD  
Basel, Switzerland

Professor Gerald Reybrouck  
Leuven, Belgium

Manfred L. Rotter, MD, DipBact  
Vienna, Austria

Theodore Sacks, MD  
Jerusalem, Israel

Dr. Bernhard M. Thimm  
Federal Republic of Germany

Professor Dr. med. H.P. Werner  
Mainz, West Germany

Professor Dr. W. Weuffen  
Greifswald, German Democratic  
Republic



# TOUGH ON STAPH



# Solve 69% of Tomorrow's Problems.

The need for an effective, cost efficient method of infection control of catheter-associated UTI has been answered. Introducing the CURITY® Infection Control Foley Catheterization System. No other system has been clinically proven to be as effective in reducing the incidence of UTI. **Clinically Proven to Substantially Reduce UTI!**

The Curity infection control system has been clinically proven to reduce the incidence of UTI by an astounding 69%!

*In vivo* studies conducted at the University of Cincinnati Medical

Center, and presented at the 86th Annual Meeting of the American Society for Microbiology, show the Curity infection control system to effectively reduce the incidence of UTI by 69% in patients catheterized from 2-30 days. In addition, the Curity test group had more total days free of infection than the control group.<sup>1</sup>

## Why the System is So Effective.


The reason the Curity® system works like no other system is because it is *like* no other system. Three major preventive measures against infection are incorporated into the unique system design:

1. A Retrograde Contamination Guard which prevents bacteria from entering the drain port.
2. The CURITY® Ultramer™ catheter, which offers greater lubricity than other coated or uncoated catheters.<sup>2</sup>
3. A Tamper Discouraging Seal which discourages disconnection at the sterile catheter-tubing junction.

Together they present an imposing set of barriers against contamination of the urinary drainage system.

## What It All Means to You.

What this means to you is now, for the first time, you have a new weapon in the fight against UTI.




The Retrograde Contamination Guard, the CURITY® Ultramer™ catheter and the Tamper Discouraging Seal are three major preventive measures against infection. Together they present an imposing set of barriers against contamination of the urinary drainage system.

A weapon that could mean substantial savings to both hospital and patient. For example, a 69% reduction in the incidence of UTI could save the average 250 bed hospital up to \$127,660 in treatment costs annually.<sup>3</sup> Much of which might not be reimbursable under DRG's.

To find out how much *your* hospital can save while improving patient care, call or write:

The Kendall Company  
Hospital Products  
One Federal Street  
Boston, MA 02101  
1-800-225-2600  
(in MA: 1-800-882-2000).



## REFERENCES:

1. Cicanec, J. and Al-Juburi, A.Z.: "Evaluation of the CURITY Retrograde Contamination Guard Urinary Drainage System in Preventing Catheter Associated Urinary Tract Infections." Presented at the 86th Annual Meeting of the American Society for Microbiology, Washington, D.C., March 1986.
2. Supportive material available on request.
3. Supportive material available on request.

**KENDALL**  
Added Value in Health Care